Prostate Cancer? Why Doing Nothing Might Be the Smartest Option

📝 Description
📌 You’ve just been told you have prostate cancer — but your doctor says you might not need treatment.
Sounds crazy? It’s not. For thousands of men, Active Surveillance is a safe, evidence-based alternative to surgery or radiation — with similar survival, fewer side effects, and more peace of mind.

In this video, we cover:
✅ What Active Surveillance actually means (it’s not “doing nothing”)
✅ Who it’s safe for — and who it isn’t
✅ What the research says, including the ProtecT Trial and Johns Hopkins data
✅ Real-life stories from men who chose this path
✅ Smart questions to ask your doctor
✅ What your monitoring plan should include
✅ And how new tools like AI MRI and genomic testing are making this even safer

💥 Plus: We bust the biggest myths — like “you’re just delaying the inevitable” or “real men treat cancer fast.”

🎯 If you or someone you care about has been diagnosed with early-stage prostate cancer — this video could change everything.

📘 FREE RESOURCE COMING SOON
Let us know in the comments:
👉 What tools or resources would help YOU feel more confident managing your diagnosis?
We’re building them for you — and we’ll release them on righttotryoptions.com

📢 Subscribe to stay ahead of cancer decisions.
New videos weekly from the Second Opinion Network — real data, real stories, no fear-mongering.

👤 Chapters
00:00 – Disclaimer & Introduction
01:00 – What Is Active Surveillance?
03:15 – Who Qualifies for It?
05:10 – What the Research Says (98% survival!)
07:20 – Real Stories (Jeff Jarvis & Peter Goss)
08:45 – Common Fears and Reassurance
10:30 – Partner and Family Pressures
12:00 – Monitoring Schedule: What It Includes
13:40 – New Tools: AI MRI & Genomic Tests
15:10 – Myth-Busting Flash Round
16:30 – Smart Questions for Your Doctor
17:30 – When Active Surveillance Isn’t Right
18:20 – What Other Men Wish They Knew
19:20 – Call to Action + What’s Coming Next

📚 Scientific References
• Hamdy et al., ProtecT Trial — NEJM, 2016: https://www.nejm.org/doi/full/10.1056...
• Tosoian et al., Johns Hopkins Active Surveillance Study — JCO, 2015
• Klotz et al., Sunnybrook 15-year AS outcomes — JCO, 2015
• NCCN Guidelines for Prostate Cancer, 2024
• EAU Guidelines on Prostate Cancer
• Eggener et al., Uptake of Active Surveillance — JAMA, 2015
• Prolaris, Oncotype, and Decipher Genomic Test Descriptions – Company sites

🧠 #Hashtags
#ProstateCancer #ActiveSurveillance #CancerDiagnosis #MensHealth #PSA #GleasonScore #SecondOpinion #Urology #CancerSupport #SecondOpinionNetwork #NoTreatmentOption #WatchfulWaiting #Biopsy #MRI #GenomicTesting #JeffJarvis #ProtecTTrial #LowRiskCancer #QualityOfLife #CancerAwareness #Oncology #CancerMyths #PatientAdvocacy